Pulmonary fibrosis

Verify with FDA CVM →

VeDDRA Code: 2259

46 adverse event reports referencing this reaction

46
Total Reports
36
Deaths
7830.0%
Death Rate

Species Most Affected

Dog 39
Cat 4
Cattle 3

Breeds Most Affected

Retriever - Golden 5
Crossbred Canine/dog 4
Retriever - Labrador 4
Domestic Shorthair 4
Cattle (unknown) 3
Coton de Tuléar 3
Shih Tzu 2
Spaniel - Cocker American 2
Terrier - Yorkshire 2
Pit Bull 2

Associated Drugs

Rabacfosadine 14
Rabacfosadine Succinate 8
Maropitant 7
Enrofloxacin 7
Prednisone 5
Oclacitinib Maleate 4
Fluralaner 4
Grapiprant 4
Gabapentin 4
Buprenorphine 4
Trenbolone; Estradiol; Tylosin Tartrate 3
Escherichia Coli K99 Antibody 3
Flunixin Meglumine 3
Isoflurane 3
Rattlesnake Vaccine 3
Metoclopramide 3
Fluid Therapy 3
Bupivacaine 3
Milbemycin Oxime + Spinosad 2
Cefovecin Sodium 2

Data Summary

Metric Value
Total reports referencing reaction 46
Reports with fatal outcome 36
Case-fatality rate (reported events) 7830.0%
Species observed 3
Breeds observed 20
Drugs associated with reaction 20

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER); reaction term coded under VeDDRA 2259.

Pulmonary fibrosis Reaction Insights

The FDA Center for Veterinary Medicine database currently lists 46 adverse event reports that reference Pulmonary fibrosis as a reaction term, including 36 reports with a death outcome — a 7830.0% case-fatality figure calculated across only those events where this reaction was coded. The reaction is indexed in the openFDA system under VeDDRA code 2259, the standardized veterinary dictionary used to normalize clinical signs across submitters. Because reports are voluntary and often describe multiple concurrent signs per animal, the volume here reflects reporting intensity rather than true incidence in the broader pet population.

Pulmonary fibrosis appears most frequently in reports for Dog (39 reports), Cat (4 reports), Cattle (3 reports) — with Dog dominating at 39 entries. Within those species, the breeds most often named alongside this reaction are Retriever - Golden (5), Crossbred Canine/dog (4), Retriever - Labrador (4). These distributions are influenced both by underlying breed popularity and by how veterinarians and owners code a given clinical sign, so they should be interpreted as a reporting fingerprint rather than a pure susceptibility ranking.

The drugs most commonly co-reported with Pulmonary fibrosis are Rabacfosadine (14 reports), Rabacfosadine Succinate (8 reports), Maropitant (7 reports), Enrofloxacin (7 reports), with Rabacfosadine appearing alongside this reaction in 14 submissions. Co-reporting does not establish that any specific product caused the reaction — FDA CVM data captures temporal association only. The value of these aggregates is in flagging which therapeutic classes appear repeatedly alongside a given clinical sign, so owners and veterinarians can ask targeted questions about medications currently in use.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial